An Overview of Intracranial Ependymomas in Adults.

brain tumors chemotherapy ependymoma glioma radiotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
05 Dec 2021
Historique:
received: 04 11 2021
revised: 29 11 2021
accepted: 03 12 2021
entrez: 10 12 2021
pubmed: 11 12 2021
medline: 11 12 2021
Statut: epublish

Résumé

Ependymomas are rare primary central nervous system tumors. They can form anywhere along the neuraxis, but in adults, these tumors predominantly occur in the spine and less frequently intracranially. Ependymal tumors represent a heterogenous group of gliomas, and the WHO 2016 classification is based essentially on a grading system, with ependymomas classified as grade I, II (classic), or III (anaplastic). In adults, surgery is the primary initial treatment, while radiotherapy is employed as an adjuvant treatment in some cases of grade II and in all cases of anaplastic ependymoma; chemotherapy is reserved for recurrent cases. In recent years, important and interesting advances in the molecular characterization of ependymomas have been made, allowing for the identification of nine molecular subgroups of ependymal tumors and moving toward subgroup-specific patients with improved risk stratification for treatment-decisions and future prospective trials. New targeted agents or immunotherapies for ependymoma patients are being explored for recurrent disease. This review summarizes recent molecular advances in the diagnosis and treatment of intracranial ependymomas including surgery, radiation therapy and systemic therapies.

Identifiants

pubmed: 34885237
pii: cancers13236128
doi: 10.3390/cancers13236128
pmc: PMC8656831
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Neurooncol Pract. 2020 Jul;7(4):391-399
pubmed: 32765890
J Clin Neurosci. 2020 May;75:112-116
pubmed: 32184042
Radiother Oncol. 2020 Sep;150:4-11
pubmed: 32502505
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
J Clin Neurosci. 2017 Dec;46:72-78
pubmed: 28890044
J Neurosurg Pediatr. 2020 May 8;:1-9
pubmed: 32384264
Acta Neuropathol. 2019 Dec;138(6):1075-1089
pubmed: 31414211
Crit Rev Oncol Hematol. 2020 Feb;146:102879
pubmed: 32005411
Acta Neuropathol. 2018 Aug;136(2):227-237
pubmed: 30019219
J Clin Neurosci. 2014 Dec;21(12):2096-101
pubmed: 25037313
Neurochirurgie. 2007 Jun;53(2-3 Pt 1):76-84
pubmed: 17445840
Pathol Oncol Res. 2010 Mar;16(1):93-9
pubmed: 19728165
J Neurooncol. 1999;45(1):61-7
pubmed: 10728911
Brain. 2007 May;130(Pt 5):1338-49
pubmed: 17449478
BMJ Case Rep. 2020 Dec 17;13(12):
pubmed: 33334744
Cancer Res. 2017 Oct 1;77(19):5419-5427
pubmed: 28807936
Anticancer Res. 2012 Nov;32(11):5067-70
pubmed: 23155280
Nat Med. 2019 May;25(5):711-712
pubmed: 31036881
Mol Clin Oncol. 2021 May;14(5):88
pubmed: 33767857
BMC Cancer. 2016 Apr 23;16:287
pubmed: 27108407
J Neurosurg. 2006 Oct;105(4):616-20
pubmed: 17044567
Acta Neuropathol. 2012 May;123(5):727-38
pubmed: 22322993
J Neurooncol. 2011 Jan;101(2):247-54
pubmed: 20526650
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Chemotherapy. 2013;59(3):176-80
pubmed: 24192541
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):387-91
pubmed: 15667957
Anticancer Res. 2011 Mar;31(3):1023-5
pubmed: 21498732
Int J Clin Exp Pathol. 2014 Dec 01;7(12):9067-71
pubmed: 25674289
J Clin Neurosci. 2020 Apr;74:250-253
pubmed: 32146015
Cancer Discov. 2019 Apr;9(4):500-509
pubmed: 30578357
Acta Neuropathol. 2018 Aug;136(2):211-226
pubmed: 29909548
J Clin Neurosci. 2021 Apr;86:79-84
pubmed: 33775351
Eur Spine J. 2018 Jul;27(Suppl 3):421-425
pubmed: 29270703
J Neurooncol. 2013 Sep;114(3):319-27
pubmed: 23813228
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
Neurology. 2009 Nov 17;73(20):1677-80
pubmed: 19917990
Cancer. 2002 Sep 1;95(5):997-1002
pubmed: 12209682
Acta Neuropathol Commun. 2020 Jul 8;8(1):101
pubmed: 32641156
Cancer. 2008 Jul 1;113(1):175-85
pubmed: 18470910
Clin Cancer Res. 2012 Apr 1;18(7):2001-11
pubmed: 22338015
Brain Pathol. 2020 Jan;30(1):3-12
pubmed: 31433520
Nat Rev Cancer. 2020 Jan;20(1):26-41
pubmed: 31601988
Acta Neurochir (Wien). 2018 Sep;160(9):1793-1799
pubmed: 29915887
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
J Endocrinol Invest. 2010 May;33(5):353-6
pubmed: 20142633
Acta Neuropathol. 2017 Nov;134(5):705-714
pubmed: 28733933
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9
pubmed: 26195750
Neuro Oncol. 2018 Nov 12;20(12):1616-1624
pubmed: 30053291
Cancer. 2005 Jul 1;104(1):143-8
pubmed: 15912507
Neuroradiol J. 2017 Jun;30(3):281-285
pubmed: 28059629
Neuro Oncol. 2021 Mar 25;23(3):468-477
pubmed: 33085768
Neuro Oncol. 2010 Sep;12(9):976-84
pubmed: 20484442
Neuro Oncol. 2018 Mar 27;20(4):445-456
pubmed: 29194500
J Neurooncol. 2017 Oct;135(1):29-36
pubmed: 28900844
Neuro Oncol. 2016 Feb;18(2):261-8
pubmed: 26323606
J Neurooncol. 2002 Dec;60(3):255-68
pubmed: 12510777
Am J Clin Oncol. 2006 Feb;29(1):106-7
pubmed: 16462515
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Cancer. 2004 Mar 15;100(6):1221-9
pubmed: 15022290
Cancer. 2009 Oct 15;115(20):4775-82
pubmed: 19569246
Neuro Oncol. 2016 Jul;18(7):902-13
pubmed: 27022130
Prog Neurol Surg. 2019;34:200-206
pubmed: 31096227
Brain Pathol. 2020 Sep;30(5):863-866
pubmed: 32502305
J Neurooncol. 2013 Dec;115(3):513-20
pubmed: 24085643
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Am J Surg Pathol. 2019 Jan;43(1):56-63
pubmed: 29266023
J Clin Neurosci. 2016 Jun;28:24-30
pubmed: 26810473
J Neurosurg Sci. 2019 Dec;63(6):661-669
pubmed: 31355622
Cancer Cell. 2011 Aug 16;20(2):143-57
pubmed: 21840481
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neurosurgery. 1999 Jan;44(1):195-8
pubmed: 9894981
Cancer Med. 2020 Jan;9(2):615-625
pubmed: 31793749
Neuro Oncol. 2015 Mar;17(3):440-7
pubmed: 25121770
J Neurooncol. 1998 Apr;37(2):131-3
pubmed: 9524091
World Neurosurg. 2019 Oct;130:405-409
pubmed: 31330336
Cancer Cytopathol. 2015 Oct;123(10):620-8
pubmed: 26235264
J Surg Res. 2009 Oct;156(2):340-51
pubmed: 19577759

Auteurs

Giuseppe Lombardi (G)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Alessandro Della Puppa (A)

Department of Neurosurgery, Department of Neuroscience, Psychology, Drug Area and Child Health (NEUROFARBA), University of Florence, Careggi University Hospital, 50134 Florence, Italy.

Marco Pizzi (M)

General Pathology and Cytopathology Unit, Department of Medicine-DMED, University of Padua, 35121 Padua, Italy.

Giulia Cerretti (G)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Camilla Bonaudo (C)

Department of Neurosurgery, Department of Neuroscience, Psychology, Drug Area and Child Health (NEUROFARBA), University of Florence, Careggi University Hospital, 50134 Florence, Italy.

Marina Paola Gardiman (MP)

General Pathology and Cytopathology Unit, Department of Medicine-DMED, University of Padua, 35121 Padua, Italy.

Angelo Dipasquale (A)

Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy.
IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.

Fabiana Gregucci (F)

Radiation Oncology Department, Advance Radiation Therapy, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, Italy.

Alice Esposito (A)

Department of Neurosurgery, Department of Neuroscience, Psychology, Drug Area and Child Health (NEUROFARBA), University of Florence, Careggi University Hospital, 50134 Florence, Italy.

Debora De Bartolo (D)

General Pathology and Cytopathology Unit, Department of Medicine-DMED, University of Padua, 35121 Padua, Italy.

Vittorina Zagonel (V)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Matteo Simonelli (M)

Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy.
IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.

Alba Fiorentino (A)

Radiation Oncology Department, Advance Radiation Therapy, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, Italy.

Francois Ducray (F)

Lyon University, Université Claude Bernard Lyon 1, 69007 Lyon, France.
Cancerology Research Center of Lyon, INSERM U1052, CNRS UMR 5286, Cancer Cell Plasticity Department, Transcriptome Diversity in Stem Cells Laboratory, 69007 Lyon, France.
Service of Neuro-Oncology, Hospices Civils de Lyon, Groupement Hospitalier Est, Neurology Hospital, 69007 Lyon, France.

Classifications MeSH